Potomac horse fever isolates
The present invention discloses novel isolates of Neorickettsia risticii , compositions comprising such isolates, vaccines and methods for using such vaccines against Potomac Horse Fever.
1. A killed or inactivated Neorickettsia risticii ( N. risticii ) bacterium of the N. risticii Oregon strain that encodes:
a strain specific antigen #1 (SSA#1) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 2;
a strain specific antigen #2 (SSA#2) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 11; and
a strain specific antigen #3 (SSA#3) comprising an amino acid sequence that has 99% or greater sequence identity with the amino acid sequence of SEQ ID NO: 18.
2. An immunogenic composition comprising the killed or inactivated N. risticii bacterium of claim 1 and a carrier.
3. The immunogenic composition of claim 2 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.
4. The immunogenic composition of claim 3 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.
5. The killed or inactivated N. risticii bacterium of claim 1 , wherein the N. risticii bacterium is the N. risticii Oregon isolate having the ATCC deposit number PTA-11232.
6. A vaccine comprising an immunogenically effective amount of the killed or inactivated N. risticii bacterium of claim 5 and a carrier.
7. The vaccine of claim 6 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.
8. The vaccine of claim 7 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.
9. The killed or inactivated N. risticii bacterium of claim 5 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.
10. The killed or inactivated N. risticii bacterium of claim 9 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.
11. The killed or inactivated N. risticii bacterium of claim 1 , wherein the N. risticii bacterium was killed or inactivated by a method selected from the group consisting of sonication, freeze-thaw techniques, pressure, treatment with heat, treatment with ultraviolet light, a chemical method, and with an enzyme.
12. The killed or inactivated N. risticii bacterium of claim 11 , wherein the chemical method is selected from the group consisting of binary ethyleneimine, formalin, beta-propiolactone, merthiolate, gluteraldehyde, sodium dodecyl sulfate, and any mixture thereof.
13. The killed or inactivated N. risticii of claim 1 comprising a nucleic acid comprising a nucleotide sequence encoding a SSA, wherein said nucleotide sequence is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, and any combination thereof.